Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

209 -0.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

208.1

Massimo

209

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

76.324

25.743

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+12.98% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

29M

20B

Apertura precedente

209.1

Chiusura precedente

209

Notizie sul Sentiment di mercato

By Acuity

21%

79%

27 / 526 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 dic 2025, 22:20 UTC

I principali Market Mover

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

I principali Market Mover

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

I principali Market Mover

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

I principali Market Mover

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Acquisizioni, Fusioni, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Discorsi di Mercato

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Discorsi di Mercato

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Discorsi di Mercato

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Acquisizioni, Fusioni, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Discorsi di Mercato

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Acquisizioni, Fusioni, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Discorsi di Mercato

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dic 2025, 13:01 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dic 2025, 11:10 UTC

Discorsi di Mercato

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dic 2025, 10:46 UTC

Discorsi di Mercato

Euro on Track For Strong Annual Performance -- Market Talk

31 dic 2025, 10:25 UTC

Discorsi di Mercato

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dic 2025, 10:23 UTC

Discorsi di Mercato

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dic 2025, 09:33 UTC

Discorsi di Mercato

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

12.98% in crescita

Previsioni per 12 mesi

Media 235 EUR  12.98%

Alto 260 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

27 / 526 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat